文献速递类风湿关节炎

在未使用生物制剂的类风湿关节炎患者中按病理生物学分层选择生物制剂治疗(STRAP与STRAP-EU):两项平行、开放标签、活检驱动的随机试验

Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials.
PubMed 文献 · Lancet Rheumatol · 2023-01-01

STRAP与STRAP-EU为两项平行、开放标签、活检驱动的3期随机试验,在未使用生物制剂的类风湿关节炎患者中按滑膜B细胞状态分层,比较利妥昔单抗、依那西普与托珠单抗的16周ACR20应答。在B细胞贫乏人群中,依那西普与托珠单抗联合组与利妥昔单抗组的ACR20应答无显著差异。滑膜B细胞贫乏与富集的二分分类未能预测利妥昔单抗的治疗应答。

要点

  • 在B细胞贫乏人群中,依那西普与托珠单抗联合组16周ACR20应答46/77(60%)对利妥昔单抗组26/44(59%),无显著差异。
  • 不良事件包括严重不良事件在各组间无差异,利妥昔单抗组6/102(6%)、依那西普组9/108(6%)、托珠单抗组3/73(4%)(p=0.53)。
  • 滑膜B细胞贫乏与富集的二分分类未能预测利妥昔单抗相较于替代治疗策略的应答。

核心结论

  • 在未使用生物制剂的类风湿关节炎人群中,滑膜B细胞贫乏与富集的二分分类未能预测利妥昔单抗相较于替代治疗策略的治疗应答。
  • 在少免疫病理类型患者中对利妥昔单抗缺乏应答,以及接受利妥昔单抗治疗的B细胞富集患者结构损伤进展风险较高,提示需进一步研究滑膜组织分析指导疾病发病机制与治疗应答的能力。

研究设计与样本

  • STRAP与STRAP-EU为两项平行、开放标签、活检驱动的分层随机3期试验,在英国的26个大学中心开展。
  • 纳入年龄18岁及以上、符合美国风湿病学会(ACR)-欧洲抗风湿病联盟分类标准且对传统合成改善病情抗风湿药(DMARDs)应答不足的未使用生物制剂类风湿关节炎患者。
  • 超声引导下滑膜活检后,根据滑膜B细胞特征将患者分为B细胞贫乏或B细胞富集,按1:1:1随机分配至静脉利妥昔单抗(第0周和第2周各1000 mg)、皮下托珠单抗(每周162 mg)或皮下依那西普(每周50 mg)。
  • 主要结局为B细胞贫乏意向治疗人群(定义为所有随机分配患者)第16周ACR20应答,汇总两项试验数据,比较依那西普与托珠单抗(联合)对比利妥昔单抗。
  • 安全性在所有至少接受一剂研究药物的患者中评估。

主要发现

  • 2015年6月8日至2019年7月4日期间,226例患者被随机分配至依那西普组(n=73)、托珠单抗组(n=74)和利妥昔单抗组(n=79)。
  • 随机化后3例患者(每组各1例)因招募前4周内接受过肠外糖皮质激素而被排除;意向治疗人群223例中168例(75%)为女性,170例(76%)为白人。
  • 在B细胞贫乏人群中,第16周ACR20应答(主要终点)在依那西普与托珠单抗联合组与利妥昔单抗组之间无显著差异:46/77(60%)对26/44(59%),比值比1.02(95%CI 0.47-2.17),p=0.97。
  • 不良事件包括严重不良事件无差异:利妥昔单抗组6/102(6%)、依那西普组9/108(6%)、托珠单抗组3/73(4%)(p=0.53)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 在少免疫病理类型患者中对利妥昔单抗缺乏应答,以及接受利妥昔单抗治疗的B细胞富集患者结构损伤进展风险较高,需进一步研究滑膜组织分析指导疾病发病机制与治疗应答的能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite highly effective targeted therapies for rheumatoid arthritis, about 40% of patients respond poorly, and predictive biomarkers for treatment choices are lacking. We did a biopsy-driven trial to compare the response to rituximab, etanercept, and tocilizumab in biologic-naive patients with rheumatoid arthritis stratified for synovial B cell status. METHODS: STRAP and STRAP-EU were two parallel, open-label, biopsy-driven, stratified, randomised, phase 3 trials done across 26 university centres in the UK and Europe. Biologic-naive patients aged 18 years or older with rheumatoid arthritis based on American College of Rheumatology (ACR)-European League Against Rheumatism classification criteria and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (DMARDs) were included. Following ultrasound-guided synovial biopsy, patients were classified as B cell poor or B cell rich according to synovial B cell signatures and randomly assigned (1:1:1) to intravenous rituximab (1000 mg at week 0 and week 2), subcutaneous tocilizumab (162 mg per week), or subcutaneous etanercept (50 mg per week). The primary outcome was the 16-week ACR20 response in the B cell-poor, intention-to-treat population (defined as all randomly assigned patients), with data pooled from the two trials, comparing etanercept and tocilizumab (grouped) versus rituximab. Safety was assessed in all patients who received at least one dose of study drug. These trials are registered with the EU Clinical Trials Register, 2014-003529-16 (STRAP) and 2017-004079-30 (STRAP-EU). FINDINGS: Between June 8, 2015, and July 4, 2019, 226 patients were randomly assigned to etanercept (n=73), tocilizumab (n=74), and rituximab (n=79). Three patients (one in each group) were excluded after randomisation because they received parenteral steroids in the 4 weeks before recruitment. 168 (75%) of 223 patients in the intention-to-treat population were women and 170 (76%) were White. In the B cell-poor population, ACR20 response at 16 weeks (primary endpoint) showed no significant differences between etanercept and tocilizumab grouped together and rituximab (46 [60%] of 77 patients vs 26 [59%] of 44; odds ratio 1·02 [95% CI 0·47-2·17], p=0·97). No differences were observed for adverse events, including serious adverse events, which occurred in six (6%) of 102 patients in the rituximab group, nine (6%) of 108 patients in the etanercept group, and three (4%) of 73 patients in the tocilizumab group (p=0·53). INTERPRETATION: In this biologic-naive population of patients with rheumatoid arthrtitis, the dichotomic classification into synovial B cell poor versus rich did not predict treatment response to B cell depletion with rituximab compared with alternative treatment strategies. However, the lack of response to rituximab in patients with a pauci-immune pathotype and the higher risk of structural damage progression in B cell-rich patients treated with rituximab warrant further investigations into the ability of synovial tissue analyses to inform disease pathogenesis and treatment response. FUNDING: UK Medical Research Council and Versus Arthritis.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Rivellese F, Nerviani A, Giorli G, et al. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials. Lancet Rheumatol. 2023. PMID: 38251532. doi:10.1016/S2665-9913(23)00241-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。